Login to Your Account

Other News To Note

Monday, November 5, 2012
• Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it will receive a $1.25 million contingent payment from Pfizer Inc., of New York, triggered by Pfizer's decision to advance the antiscarring therapy EXC 001 into a Phase II study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription